BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37754495)

  • 1. Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
    Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
    Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid Tumors.
    Carreras MJ; Renedo-Miró B; Valdivia C; Tomás-Guillén E; Farriols A; Mañós L; Vidal J; Alcalde M; De la Paz I; Jiménez-Lozano I; Palacio-Lacambra ME; Sabaté N; Felip E; Garralda E; Garau M; Gorgas MQ; Monterde J; Tabernero J
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
    Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia.
    Parera Roig M; Colomé DC; Colomer GB; Sardo EG; Tournour MA; Fernández SG; Ominetti AI; Juvanteny EP; Polo JLM; Jobal DB; Espejo-Herrera N
    Curr Oncol; 2024 Apr; 31(4):2145-2157. PubMed ID: 38668062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
    Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
    JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
    Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
    Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
    Nesline MK; Knight T; Colman S; Patel K
    Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in oncology: Effects on economy and therapeutic innovations.
    Hübel K; Kron F; Lux MP
    Eur J Cancer; 2020 Nov; 139():10-19. PubMed ID: 32950935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
    Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
    J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
    Hradecká I; Ríhová B; Horová R; Demlová R
    Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia.
    Guarga L; Paco N; Vela E; Clèries M; Corral J; Delgadillo J; Pontes C; Borràs JM
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
    da Veiga CRP; da Veiga CP; Drummond-Lage AP
    Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.